April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Subgroup Analyses of Visual Acuity Outcomes in the CRUISE Study of Intravitreal Ranibizumab in Patients with Macular Edema Following Central Retinal Vein Occlusion
Author Affiliations & Notes
  • C. D. Regillo
    Retina Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • R. Rubio
    Genentech, Inc., South San Francisco, California
  • N. Saroj
    Genentech, Inc., South San Francisco, California
  • Z. Li
    Genentech, Inc., South San Francisco, California
  • A. Rundle
    Genentech, Inc., South San Francisco, California
  • S. Gray
    Genentech, Inc., South San Francisco, California
  • W. Yee Murahashi
    Genentech, Inc., South San Francisco, California
  • Footnotes
    Commercial Relationships  C.D. Regillo, Genentech, Inc., F; Alcon, F; Regeneron, F; Novartis, F; QLT, F; Allergan, F; Alimera, F; NeoVista, F; NIH, F; Genentech, Inc., C; Novartis, C; QLT, C; Alcon, C; R. Rubio, Genentech, Inc., E; N. Saroj, Genentech, Inc., E; Z. Li, Genentech, Inc., E; A. Rundle, Genentech, Inc., E; S. Gray, Genentech, Inc., E; W. Yee Murahashi, Genentech, Inc., E.
  • Footnotes
    Support  NIH
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3566. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. D. Regillo, R. Rubio, N. Saroj, Z. Li, A. Rundle, S. Gray, W. Yee Murahashi; Subgroup Analyses of Visual Acuity Outcomes in the CRUISE Study of Intravitreal Ranibizumab in Patients with Macular Edema Following Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3566.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

Subgroup analyses of efficacy outcomes for patients with macular edema (ME) following central retinal vein occlusion (CRVO) who participated in CRUISE.

 
Methods:
 

Phase III, double-masked, controlled study of 392 patients with ME (central subfield thickness ≥250 µm) following CRVO randomized to receive 6 monthly intravitreal injections of 0.3 mg (n=132) or 0.5 mg (n=130) ranibizumab or sham injections (n=130) followed by 6 months of observation, during which all patients could receive ranibizumab PRN if prespecified criteria were met. Primary efficacy endpoint was mean change from baseline best-corrected visual acuity (BCVA) at Month 6. Prespecified subgroup analyses included change from BCVA according to baseline BCVA (≤34, 35-54, or ≥55 Early Treatment Diabetic Retinopathy Study [ETDRS] letters) and baseline optical coherence tomography (OCT)-assessed central foveal thickness (CFT; <450 µm, ≥450 µm). Post hoc analysis of BCVA outcomes according to time from diagnosis to screening (<3 months, ≥3 months) was also performed.

 
Results:
 

At Month 6, patients in the sham, 0.3 mg, and 0.5 mg groups had gained a mean (SD) of 0.8 (16.2), 12.7 (15.9), and 14.9 (13.2) letters from baseline (p<0.0001 each ranibizumab group vs. sham). The treatment group differences in BCVA outcomes were maintained when analyzed by subgroup. For ranibizumab-treated patients, change in BCVA was greater for those with worse baseline BCVA and baseline CFT ≥450 µm (Table).

 
Conclusions:
 

Ranibizumab provided visual benefit to patients with ME following CRVO. Patients with the worst BCVA and greatest CFT at baseline tended to derive the most benefit.  

 
Clinical Trial:
 

www.clinicaltrials.gov NCT00485836

 
Keywords: vascular occlusion/vascular occlusive disease • edema • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×